BB Biotech’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BB Biotech’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$26.8M	Hold	2,200,000	–	–	0.67%	29
2018 Q4	$25.1M	Hold	2,200,000	–	–	0.8%	28
2018 Q3	$47.7M	Hold	2,200,000	–	–	1.26%	25
2018 Q2	$38.9M	Hold	2,200,000	–	–	1.12%	22
2018 Q1	$46.3M	Hold	2,200,000	–	–	1.28%	20
2017 Q4	$31.9M	Hold	2,200,000	–	–	0.9%	20
2017 Q3	$34.7M	Buy	2,200,000 +50,000	+2%	+$734K	0.96%	20
2017 Q2	$26.7M	Buy	2,150,000 +225,000	+12%	+$2.61M	0.82%	22
2017 Q1	$31.3M	Buy	1,925,000 +350,000	+22%	+$5.07M	1.02%	21
2016 Q4	$23.8M	Buy	1,575,000 +225,000	+17%	+$3.18M	0.88%	21
2016 Q3	$20.6M	Buy	1,350,000 +650,000	+93%	+$26.3M	0.72%	22
2016 Q2	$27.2M	Buy	+700,000	New	+$25.2M	1.07%	21

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BB Biotech's ITCI Position: Q1 2019 in Review

BB Biotech held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q1 2019 at 2,200,000 shares worth $26.8M. The position accounts for 0.67% of the portfolio, ranked #29.

BB Biotech first reported a position in ITCI in Q2 2016 and has held it in 12 quarters since. The position peaked at $47.7M in Q3 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2019.

BB Biotech held 2,200,000 shares of Intra-Cellular Therapies Inc. worth $26.8M as of Q1 2019.
BB Biotech left its Intra-Cellular Therapies Inc. share count unchanged in Q1 2019.
Intra-Cellular Therapies Inc. made up 0.67% of BB Biotech's portfolio in Q1 2019, its #29 holding.
BB Biotech first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and has held it in 12 quarters since.
BB Biotech's Intra-Cellular Therapies Inc. position peaked at $47.7M in Q3 2018.
127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.